Oncology金沙网站

金沙登录网址



Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer.   金沙登录网址

To accomplish this, we focus on research and development and our commercial capabilities to deliver a new generation of medicines that have the potential to redefine cancer treatment.金沙登录网址


金沙网站


金沙网站


金沙网站

We’re targeting the underlying biological drivers of cancer by focusing on four different scientific platforms: Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response, and Antibody Drug Conjugates.


金沙网站

We’re concentrating on biomarker-driven indications to dramatically improve five-year survival in five tumour types, including ovarian cancer and non-small cell lung cancer (NSCLC).


金沙网站

Our patient-centric approach focuses on 1) identifying and treating patients earlier in the course of their disease with curative intent; and 2) supporting relapsed and refractory patients by tackling primary or acquired resistance.


金沙网站

We’re expanding our presence across geographies to deliver timely treatments to patients in the US, UK, Italy, France, Germany, Spain, Japan, and China.





金沙登录网址

Among the many different types of cancer that our scientists explore, we are developing new treatment approaches for the following types of cancer:


金沙登录网址

We’re concentrating on four scientific platforms that we believe show the greatest potential for yielding effective medicines for cancer patients.


  • 金沙网站

    Activating the body’s own immune system to help fight cancer


  • 金沙网站

    Targeting the genetic mutations and resistance mechanisms that enable cancer cells to evade treatment, survive, and proliferate


  • 金沙网站

    Targeting the DNA repair process to block cancer cells’ ability to reproduce


  • 金沙网站

    Delivering highly potent cancer-killing agents directly to cancer cells via a linker attached to a targeted antibody



金沙网站


As part of our commitment to Oncology, we’re constantly working on new and exciting workstreams.
金沙网站

金沙网站


金沙登录网址

Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance.  Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care.
 


The great advance of personalised healthcare, in oncology, has been the realisation that some tumours are driven by individual genes. So if you can find out which genes these are, you can develop a medicine that's best for that tumour, and then select patients that are best for that medicine.

Ruth March Senior Vice-President of Precision Medicine, R&D Oncology

Collaboration in Oncology金沙网站

金沙登录网址


金沙登录网址

Genomics is the foundation of what science can do to understand the causes of disease and develop new medicines.


金沙登录网址

and help us deliver life-changing medicines

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.


金沙网站


金沙网站

 

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval, and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).


金沙登录网址

Phase I

金沙网站

  • AZD0466 haematological and solid tumours
  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD5153 solid tumours, haematological malignancies
  • AZD5991 haematalogical malignancies
  • AZD7648 haematological and solid tumours
  • AZD9496 oestrogen receptor +ve breast cancer
  • Calquence + ceralasertib (AZD6738) haematological malignancies
  • Calquence + danvatirsen haematological malignancies
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + Koselugo (selumetinib) solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + CTx 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI5083 solid tumours
  • MEDI5395 solid tumours
  • oleclumab + Tagrisso EGFRm NSCLC

Phase II

金沙网站

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • adavosertib ovarian cancer, solid tumours
  • AZD2811 solid tumours, haematological malignancies
  • AZD4635 prostate cancer
  • AZD9833 oestrogen receptor +ve breast cancer
  • capivasertib breast cancer
  • capivasertib prostate cancer
  • Imfinzi (platform) COAST non small cell lung cancer
  • Imfinzi (platform) NeoCOAST non small cell lung cancer
  • Imfinzi + AZD4635 prostate cancer
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + FOLFOX + bevacizumab COLUMBIA 1 1st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + adavosertib solid tumours
  • Lynparza + ceralasertib (AZD6738) VIOLETTE breast cancer
  • Lynparza + Imfinzi MEDIOLA ovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • MEDI5752 solid tumours
  • oleclumab + AZD4635 prostate cancer
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

金沙网站

  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • Enhertu DESTINY-Breast01 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Koselugo (selumetinib) SPRINT paediatric neurofibromatosis type-1
  • Lumoxiti 3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer

LCM Projects

金沙网站

  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-RR relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + venetoclax + obinutuzumab 1st-line chronic lymphocytic leukaemia
  • Enhertu HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-CRC01 HER2-expressing advanced colorectal cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric02 HER2-positive gastric cancer that cannot be surgically removed or has spread
  • Enhertu DESTINY-Breast02 HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi solid tumours
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage I-III) NSCLC
  • Imfinzi + SoC CASPIAN 1st-line extensive-stage small-cell lung cancer
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza + cediranib CONCERTO recurrent platinum-resistant ovarian cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage 3 EGFRm non-small cell lung cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer

金沙网站


金沙登录网址

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.


Arimidex 金沙网站

anastrozole

Calquence金沙网站

acalabrutinib

Casodex, Cosudex金沙网站

bicalutamide

Enhertu金沙网站

trastuzumab deruxtecan

Faslodex 金沙网站

fulvestrant

Imfinzi金沙网站

durvalumab

Iressa金沙网站

gefitinib

Lynparza金沙网站

olaparib

Tagrisso金沙网站

osimertinib

Zoladex金沙网站

goserelin acetate implant


金沙网站



References 

1.   Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. https://doi.org/10.1186/s40425-018-0360-8.

2.     McGowan CH, Russell P. Human Wee 1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993 Jan; 12(1):75-85.

3.     Tominaga Y, Li C, Wang RH, Deng CX. Murine Wee1 plays a critical role in cell cycle regulation and preimplantation stages of embryonic development. J Biol Sci. 2006; 2(4):161-170.

4.     Guertin AD, Li J, Liu Y, et al. Preclinical evaluation of the Wee-1 inhibitor MK-1775 as a single-agent anticancer therapy. Mol Cancer Ther. 2013 Aug;12(8):1442-1452.

5.     Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013 Oct 1; 12(19), 3159-3164.

6.     Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee-1 kinase by MK-1775 selectively sensitizes p53-edficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov; 8(11):2992-3000.

7.     Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-7464.

8.     Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-644.

9.     Clark AS, West K Streicher S, Dennis PA. Constitutive and inducible AKT activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002 Jul;1(9):707-717.

10.  Huang W-C, Hung M-C. Induction of AKT activity by chemotherapy confers acquired resistance. J Formos Med Assoc. 2009 Mar;108(3):180-194.

11.  Selli, C., et al. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016; 18: 118 .

12.  Basaran GA, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144-155..

13.  Mitri, Z. et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012; 2012: 743193. doi: 10.1155/2012/743193. Accessed April 2019.

14.  Carlson B. HER2 TESTS: How Do We Choose? Biotechnol Healthc. 2008; 5(3): 23–27.

15.  The Royal Marsden NHS Foundation Trust. A beginner’s guide to BRCA1 and BRCA2. Available at: https://www.royalmarsden.nhs.uk/sites/default/files/files_trust/beginners-guide-to-brca1-andbrca2.PDF. Accessed May 2019.

 




Veeva ID: Z4-22142  
Date of Prep: March 2020
Date of Expiry: March 2022